US approves new Parkinson’s drug developed by AbbVie
Most outlets reported the FDA’s approval of AbbVie’s Parkinson’s drug, tavapadon, and noted the company’s acquisition of Cerevel Therapeutics in 2023 to gain access to the drug. ARY News mentioned the $8.7 billion acquisition amount, while ProPakistani provided a more concise summary of the approval and acquisition without specifying the financial figure.
Summary generated by HarZaviya from the headlines and excerpts of the 2 outlets below. Each outlet's own headline is listed under it.
Same story from 2 outlets
Each outlet's own headline, most recent first — read any at its source.
-
US FDA Approves New Parkinson’s Drug
The US Food and Drug Administration has approved AbbVie’s treatment for Parkinson’s disease in adults. The drug, tavapadon, was acquired… Read More
-
Tavapadon: US approves AbbVie’s drug for Parkinson’s disease
The drug tavapadon, which AbbVie gained access to through its $8.7 billion acquisition of Cerevel Therapeutics in 2023, comes as...
2 articles from 2 outlets, 26 Sep–28 Sep 2026. Headlines and links belong to their outlets — HarZaviya links out and never copies article text. What does % identical mean?